Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M&A Activity Up Year-Over-Year, Driven By Tax-Inversion Deals And Diversification

This article was originally published in The Pink Sheet Daily

Executive Summary

The Actavis/Forest deal was the largest deal in the first quarter, but was among 62 deals in total that were signed in the biopharma sector during the quarter.

You may also be interested in...



European Notebook: Industry’s Post-EU Election Goals; IMI2 Gets Under Way; FDA/EMA Tie-Up On Childhood Gaucher Studies

Worries about science bases drew European politicians to the AstraZeneca/Pfizer merger debate; the European industry calls for EU-wide R&D agenda, standards of care; IMI2 public-private partnership gets under way; FDA and EMA to collaborate on clinical trials for childhood Gaucher disease.

Actavis’ Big Bet On A Diversified Hybrid Model

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.

Deals Of The Week: Keeping Score – Valeant Wants Actavis, Which Covets Warner Chilcott …

Meanwhile, companies like Mylan and Novartis also reportedly have joined the Actavis chase. In addition, there’s been deal-making news from Elan and Theravance, Merck-Serono and Quintiles, and AbbVie and Alvine.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS077079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel